Options Wonderland

[3xBuBu]

The race for a coronavirus cure is picking up speed.

https://ih.advfn.com/stock-market/stock-news/82654109/moderna-viacomcbs-goldman-sachs-stocks-that-def

This summer three experimental vaccines will enter Phase 3 trials, the final stage of testing meant to determine their safety and effectiveness, The Wall Street Journal reported on Wednesday.
Moderna's vaccine is set to be first, (MRNA)
followed by one co-developed by Oxford University and AstraZeneca PLC (AZN)
and one by Johnson & Johnson. (JNJ)
Moderna shares gained 3.2% Wednesday.

.
.
.

J&J exec: Our coronavirus vaccine is aiming for a 70% success rate in trials
https://finance.yahoo.com/news/jj-coronavirus-vaccine-aims-for-70-success-rate-125444337.html


Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine

https://finance.yahoo.com/news/emergent-ebs-manufacture-astrazenecas-coronavirus-125112928.html

Small-cap Emergent BioSolutions (NYSE:EBS) has landed another contract to manufacture a possible COVID-19 vaccine, this time with European pharmaceutical giant AstraZeneca. Of course, the contract, said to be worth as much as $87 million, hinges on whether AstraZeneca's vaccine gets approved by the Food and Drug Administration for human use.

Emergent is a contract development and manufacturing organization that has relationships with many biotech and pharmaceutical companies (not to mention the federal government). Back in April, it inked a similar deal with Johnson & Johnson worth up to $135 million.

https://www.fool.com/investing/2020/06/11/emergent-biosolutions-will-manufacture-astrazeneca.aspx


Teva Wins Narcan Patent Battle — Sending Its Biotech Rivals Plunging

https://www.investors.com/news/technology/opioid-overdose-treatment-teva-wins-battle-copy-emergent-narcan/?src=A00220&yptr=yahoo

Emergent BioSolutions (EBS) and Opiant Pharmaceuticals (OPNT) stocks plunged Monday after Teva Pharmaceutical (TEVA) won the right to produce a knock-off their opioid overdose treatment, Narcan.